December 18, 2008
TARO FILES FORM 6-K SUPPLEMENTING ITS PRELIMINARY THIRD QUARTER AND YEAR-TO-DATE 2008 FINANCIAL RESULTS
Hawthorne, NY, December 18, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today filed a Form 6-K with the Securities and Exchange Commission supplementing its press release dated November 11, 2008 by providing in tabular form its preliminary, unaudited financial results for the nine months ended September 30, 2008, and updated information on its liquidity.
More 
November 11, 2008
TARO PROVIDES PRELIMINARY THIRD QUARTER AND YEAR-TO-DATE 2008 FINANCIAL RESULTS
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Sept. 10, 2008--Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today provided information on its financial performance for the third quarter and first nine months of 2008.
More
September 10, 2008
Taro Sends Letter to Update Shareholders on Status of Litigation with Sun
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Sept. 10, 2008--Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," Pink Sheets: TAROF) today announced that it is sending a letter to its shareholders updating them on the status of litigation with Sun Pharmaceutical Industries Ltd.
More
July 31, 2008
TARO AND NEXTWAVE ANNOUNCE AGREEMENT TO CO-PROMOTE OVIDE® IN THE UNITED STATES
Agreement Doubles Size of OVIDE® Sales Force
Hawthorne, N.Y. and Vernon Hills, Il., July 31, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro” or the “Company” Pink Sheets: TAROF) and NextWave Pharmaceuticals, Inc. (“NextWave”) today announced that Taro’s U.S. subsidiary (“Taro USA”) and NextWave have entered into an agreement to co-promote OVIDE® (malathion) Lotion, 0.5% (“OVIDE”) in the United States.
More
July 28, 2008
TARO UPDATES SHAREHOLDERS ON FINANCIAL TURNAROUND;
PROJECTS SIGNIFICANT GROWTH IN NET SALES IN 2008;
REAFFIRMS BOARD’S RECOMMENDATION NOT TO TENDER SHARES
Hawthorne, NY, July 28, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today announced that it is sending a letter to its shareholders updating them on the status of the Company’s financial and operational turnaround.
More
July 23, 2008
TARO PROVIDES PRELIMINARY FIRST HALF 2008 FINANCIAL RESULTS
First Half 2008 Net Income Nears Full Year 2007 Net Income
Hawthorne, NY, July 23, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,”
Pink Sheets: TAROF) today provided information on its financial performance for the first half
of 2008.
More
July 10, 2008
TARO BOARD CONCLUDES THAT SUN TENDER OFFER IS FINANCIALLY INADEQUATE, IS A "SHAM" OFFER AND VIOLATES ISRAELI LAW; URGES SHAREHOLDERS NOT TO TENDER THEIR SHARES
Hawthorne, NY, July 10, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) said today that its Board of Directors (with Drs. Barrie Levitt and Daniel Moros and Ms. Tal Levitt neither participating in the deliberations nor voting) has unanimously concluded that Sun’s offer is financially inadequate and is a "sham" offer, because we believe Sun knows that it will not be accepted by the shareholders.
More
June 30, 2008
TARO BOARD OF DIRECTORS TO EVALUATE UNSOLICITED TENDER OFFER FROM SUN PHARMACEUTICAL INDUSTRIES LTD.; TARO ASKS SHAREHOLDERS NOT TO TAKE ANY ACTION AT THIS TIME
Hawthorne, NY, June 30, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro” or the “Company”) (Pink Sheets: TAROF) said today that it would have no formal comment on the unsolicited tender offer commenced today by a subsidiary of Sun Pharmaceutical Industries Ltd. (“Sun”), for all shares of Taro common stock at a price of $7.75 per share until Taro's Board of Directors has an opportunity to review and evaluate the full details of the offer.
More
June 23, 2008
TARO RECEIVES FINAL FDA APPROVAL FOR RX CETIRIZINE HYDROCHLORIDE SYRUP ANDA Generic Equivalent to Zyrtec® Syrup
Hawthorne, NY, June 23, 2008 -- Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF, “Taro”, the “Company”) reported today that it has received final approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for prescription Cetirizine Hydrochloride Syrup, 1 mg / 1 mL (“cetirizine syrup”). Taro had received tentative approval for this ANDA in October 2007.
More
June 19, 2008
TARO SENDS LETTER TO UPDATE SHAREHOLDERS ON LATEST DEVELOPMENTS REGARDING THE TERMINATED SUN MERGER AGREEMENT
Hawthorne, NY, June 19, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today announced that it is sending a letter to its shareholders updating them on certain developments regarding the previously announced termination of its merger agreement with a subsidiary of Sun Pharmaceutical Industries Ltd.
More
May 28, 2008
TARO TERMINATES MERGER AGREEMENT WITH SUN PHARMACEUTICAL INDUSTRIES LTD.
Hawthorne, NY, May 28, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today announced that its Board of Directors unanimously voted to terminate the May 18, 2007 merger agreement (the “Merger Agreement”) between the Company and Aditya Acquisition Company Ltd., a subsidiary of Sun Pharmaceutical Industries Ltd. (“Sun,” Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715). The Merger Agreement provided for the acquisition of Taro by Sun for $7.75 per share and allowed either party to terminate after December 31, 2007.
More
April 28, 2008
TARO REACHES AGREEMENT IN PRINCIPLE TO SETTLE SECURITIES LAWSUIT
Hawthorne, NY, April 28, 2008. Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) announced today that the parties in the purported securities class action captioned Loretta Zwickel v. Taro Pharmaceutical Industries Ltd., et al., Case No. 04-CV-05969 (United States District Court for the Southern District of New York) have reached an agreement in principle to settle all claims asserted against all defendants in the action. The settlement is subject to the execution of definitive documentation, notice to the purported shareholder class and final approval of the settlement by the court at a hearing to be scheduled in the near future.
More
April 22, 2008
TARO RECEIVES FINAL FDA APPROVAL FOR CETIRIZINE HYDROCHLORIDE ORAL SOLUTION ANDA
Generic Equivalent to Over-the-Counter Zyrtec® Oral Solution
Hawthorne, NY, April 22, 2008 -- Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF, “Taro”, the “Company”) reported today that it has received final approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for cetirizine hydrochloride oral solution, 1 mg / 1 mL (“Cetirizine Oral Solution”). The product will be marketed by Taro’s U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc.
More
April 10, 2008
TARO APPOINTS NEW CHIEF FINANCIAL OFFICER Hawthorne, NY, April 10, 2008. Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) announced today that Ron Kolker, C.P.A., has been appointed to the position of Senior Vice President, Chief Financial Officer of the Company and of the Company’s U.S. subsidiary, Taro Pharmaceuticals U.S.A., Inc. (“Taro USA”).
Mr. Kolker joined Taro in 1994 and has held a number of roles in finance at the Company with increasing responsibility. He most recently held the position of Group Vice President, Corporate Controller in both the Company and Taro USA, and also served as the Company’s Interim Chief Financial Officer for part of 2007. Mr. Kolker is a Certified Public Accountant and holds an MBA in Finance and Accounting. Mr. Kolker replaces Thomas E. McClary, who is no longer with the Company.
More
April 3, 2008
TARO RECEIVES TENTATIVE FDA APPROVAL FOR LAMOTRIGINE TABLETS ANDA Generic Equivalent to GlaxoSmithKline’s Lamictal® Tablets, 25 mg, 100 mg, 150 mg and 200 mg
Hawthorne, NY, April 3, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the "Company,” Pink Sheets: TAROF) reported today that it has received tentative approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Lamotrigine Tablets 25 mg, 100 mg, 150 mg, and 200 mg (“Lamotrigine Tablets”).
More
March 25, 2008
TARO RECEIVES FDA APPROVAL FOR ONDANSETRON HYDROCHLORIDE INJECTION USP, 2 mg/mL ANDA
Generic Equivalent to GlaxoSmithKline’s Zofran® Injection
Hawthorne, NY, March 25, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) reported today that it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Ondansetron Hydrochloride Injection USP, 2 mg/mL (“Ondansetron Injection”).
More
February 19, 2008
TARO PROVIDES PRELIMINARY 2007 FULL YEAR RESULTS
Hawthorne, New York, Febrary 19, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” Pink Sheets: TAROF) today provided information for the year ended December 31, 2007.
The Company cautioned that the financial information being presented is both unaudited and subject to further review and possible change. Additionally, these results do not provide complete financial information and both the 2006 and the 2007 results are subject to audit by the Company's outside auditors. These results have not been and will not be subject to quarterly review procedures. However, subject to the foreging caveats, the Company believes that the information below represents the best information currently available to Taro management.
More
January 22, 2008
TARO RECEIVES FDA APPROVAL OF NEW DRUG APPLICATION FOR FLO-PREDTM PREDNISOLONE ACETATE ORAL SUSPENSION
Hawthorne, New York, January 22, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” Pink Sheets: TAROF) reported today that its U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc ("Taro USA") has received approval from the U.S. Food and Drug Administration for its New Drug Application (NDA) for Flo-PredTM (prednisolone acetate oral suspension) equivalent to 5 mg/5 mL and 15 mg/5 mL prednisolone in Taro's patent-protected NonSpilTM liquid drug delivery system.
More
January 09, 2008
TARO TO LAUNCH OXCARBAZEPINE IN THE UNITED STATES
Hawthorne, New York, January 9, 2008 – Taro Pharmaceutical Industries Ltd. (“Taro,” Pink Sheets: TAROF) reported today that it settled a pending lawsuit with Novartis and will be launching Oxcarbazepine Tablets 150 mg, 300 mg, and 600 mg (“Oxcarbazepine Tablets”) in the United States.
More
January 07, 2008
TARO TO CHALLENGE ASSESSMENT ORDER FROM ISRAEL INCOME TAX AUTHORITY
Hawthorne, NY, January 7, 2008 - Taro Pharmaceutical Industries Ltd. Company Says Order Is Confiscatory and Reflects Double Taxation; May Seek Intervention of U.S. Government
More